Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus

Bertram Pitt¹ · Gabriel Steg² · Lawrence A. Leiter³ · Deepak L. Bhatt⁴

Published online: 24 December 2021

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to: Cardiovascular Drugs and Therapy

<https://doi.org/10.1007/s10557-021-07291-y>

The original article has been corrected. References 5 and 6 have been switched. Reference 5 “Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. *N Eng J Med*. 2021;384:117–28” should be “Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. *N Eng J Med*. 2021;384:129–39.” Reference 6 “Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. *N Eng J Med*. 2021;384:129–39” should be “Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. *N Eng J Med*. 2021;384:117–28.”

5. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. *N Eng J Med*. 2021;384:129–39.

6. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. *N Eng J Med*. 2021;384:117–28.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10557-021-07291-y>.

✉ Deepak L. Bhatt
DLBhattMD@post.Harvard.edu

¹ University of Michigan, Ann Arbor, MI, USA

² Université de Paris, Hôpital Bichat, Paris, France

³ Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

⁴ Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA